Methods for the inhibition of angiogenesis with 6-amino EM-12
OwnerRobert D'Amatoinventor
Life of this patent
Estimating the term…
Abstract
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
Claims21
A method of treating an eye condition associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138,
- 19
A method of treating a non-tumor blood condition associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138,
- 20
A method of treating an ulcerative disease associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138,
- 21
A method of treating a skin condition associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138,
- 22
A method of treating an immune disease associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138,
- 23
- acquired immune deficiency syndrome, and osteoarthritis.
A method of treating an infection associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138,
- 24
A method for inhibiting undesired angiogenesis in a human or animal wherein the angiogenesis is associated with a condition selected from the group consisting of trauma, sjogren's syndrome, phylectenulosis, sarcoid, pseudoxanthoma elasticum, Stargardt's disease, Paget's disease, Lyme's disease, par planitis, pyogenic granulomas, and lipid degeneration comprising administering to the human or animal an angiogenesis inhibiting amount of EM-138,
- 25
A method of inhibiting undesired angiogenesis in a human or animal wherein the angiogenesis is associated with a condition selected from the group consisting of Crohn's disease and chronic inflammation comprising administering to the human or animal an angiogenesis inhibiting amount of EM-138,
- 26
A method of inhibiting undesired angiogenesis in a human or animal wherein the angiogenesis is associated with abnormal amount of EM-138,
- 27
Dependencies are inferred from the claim text.